Early-onset type 2 diabetes impairs skeletal acquisition in the male TALLYHO/JngJ mouse

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3806-3816

  Devlin, M J ^a   Van Vliet, M ^a   Motyl, K ^b   Karim, L ^a   Brooks, D J ^a   Louis, L ^a   Conlon, C ^a   Rosen, C J ^b   Bouxsein, M L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; INSULIN; LEPTIN; N PEPTIDE 1; PEPTIDE; PROCOLLAGEN; PROCOLLAGEN 1; UNCLASSIFIED DRUG; SUGAR INTAKE;

ADIPOCYTE; ADIPOGENESIS; AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DEFECT; BONE DENSITOMETRY; BONE DENSITY; BONE MARROW STROMA CELL; BONE MASS; BONE STRENGTH; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; EARLY ONSET NON INSULIN DEPENDENT DIABETES MELLITUS; FEMUR; GENOTYPE; HISTOLOGY; HYPERINSULINEMIA; HYPERLEPTINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; MALE; MORPHOMETRICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; POROSITY; PROTEIN BLOOD LEVEL; RIGIDITY; THICKNESS; TRABECULAR BONE; WHITE ADIPOSE TISSUE; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; LIPID DIET; MOUSE MUTANT; MUTANT MOUSE STRAIN; ONSET AGE; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY; SUGAR INTAKE;

AGE FACTORS; AGE OF ONSET; ANIMALS; BONE DENSITY; BONE DEVELOPMENT; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIETARY SUCROSE; MALE; MICE; MICE, MUTANT STRAINS; MICE, OBESE; OSTEOGENESIS;

EID: 84907212909     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1041     Document Type: Article

References (55)

1. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366: 2247-2256.
2. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700.
3. Bailey DA. The Saskatchewan Pediatric Bone Mineral Accrual Study: bone mineral acquisition during the growing years. Int J Sports Med. 1997;18(suppl 3):S191-S194.
4. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 1991;73:555-563.
5. Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R. Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 1991;72:602-606.
6. Schwartz AV, Vittinghoff E, Bauer DC, et al. Study of Osteoporotic Fractures Research Group, Osteoporotic Fractures inMenResearch Group, Health A, Body Composition Research Group: association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305:2184-2192.
7. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent ofBMDor diabetic complications. J Bone Miner Res. 2009; 24:702-709.
8. Masse PG, Pacifique MB, Tranchant CC, et al. Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in young adult women: a disease complication often ignored or neglected. J Am Coll Nutr. 2010;29:419-429.
9. Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab. 1998;11:413-419.
10. Pollock NK, Bernard PJ, Wenger K, et al. Lower bone mass in prepubertal overweight children with prediabetes. J Bone Miner Res. 2010;25:2760-2769.
11. Afghani A, Cruz ML, Goran MI. Impaired glucose tolerance and bone mineral content in overweight Latino children with a family history of type 2 diabetes. Diabetes Care. 2005;28:372-378.
12. Di Iorgi N, Mo AO, Grimm K, Wren TA, Dorey F, Gilsanz V. Bone acquisition in healthy young females is reciprocally related to marrow adiposity. J Clin Endocrinol Metab. 2010;95:2977-2982.
13. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem. 2007;102:1343-1357.
14. Shen W, Chen J, Gantz M, et al. MRI-measured pelvic bone marrow adipose tissue is inversely related to DXA-measured bone mineral in younger and older adults. Eur J Clin Nutr. 2012;66:983-988.
15. Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone. 2012;50:276-288.
16. Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99:411-424.
17. Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int. 1995;57:422-425.
18. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulinlike growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int. 1998; 63:107-111.
19. Kim JH, Stewart TP, Soltani-Bejnood M, et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol. 2006;191:437-446.
20. Kim JH, Sen S, Avery CS, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics. 2001;74: 273-286.
21. Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Rev. 2007;28:48-83.
22. Kim JH, Saxton AM. The TALLYHO mouse as a model of human type 2 diabetes. Methods Mol Biol. 2012;933:75-87.
23. Mathews CE, Leiter EH. Rodent models for the study of diabetes. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, eds. Joslin's Diabetes Mellitus. 14th ed. Philadelphia: Lippincott Williams, Willkins; 2005:292-328.
24. Heikkinen S, Argmann CA, Champy MF, Auwerx J. Evaluation of glucose homeostasis. Curr Protoc Mol Biol 2007;Chapter 29:Unit 29B
25. Bouxsein ML, Devlin MJ, Glatt V, Dhillon H, Pierroz DD, Ferrari SL. Mice lacking-adrenergic receptors have increased bone mass, but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology. 2009;150:144-152.
26. Rosen CJ, Ackert-Bicknell CL, Adamo ML, et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone. 2004;35:1046-1058.
27. Devlin MJ, CloutierAM,ThomasNA,et al. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res. 2010;25:2078-2088.
28. Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res. 2007;22:1197-1207.
29. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25:1468-1486.
30. Turello R, Snyder D, Hartman HA. A modification the osmium tetroxide post-fixation technique for the demonstration of extracellular lipid in paraffin-embedded tissue sections. J Histotechnol. 1984;7:75-77.
31. Fretz JA, Nelson T, Xi Y, Adams DJ, Rosen CJ, Horowitz MC. Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse. Endocrinology. 2010;151:1611-1621.
32. Scheller EL, Troiano N, Vanhoutan JN, et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol. 2014;537:123-139.
33. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology. 2005;146:655-665.
34. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28:2-17.
35. Roberts B, Thomas N, Brimer D, Proctor A, Bouxsein ML. Use of a novel microindentation system demonstrates age-and strain related differences in cortical bone material properties in C3H/HeJ and C57Bl6/J mice. J Bone Miner Res. 2009;24 (Suppl 1).
36. Karim L, Vashishth D. Heterogeneous glycation of cancellous bone and its association with bone quality and fragility. PloS One. 2012; 7:e35047.
37. DeMambro VE, Clemmons DR, Horton LG, et al. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology. 2008;149:2051-2061.
38. Lang DH, Sharkey NA, Lionikas A, et al. Adjusting data to body size: a comparison of methods as applied to quantitative trait loci analysis of musculoskeletal phenotypes. J Bone Miner Res. 2005; 20:748-757.
39. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28:313-324.
40. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045-5055.
41. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380-2386.
42. McCabe L, Zhang J, Raehtz S. Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2011;21:187-206.
43. Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res. 2013;28(8):1721-1728.
44. Baum T, Yap SP, Karampinos DC, et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? J Magn Reson Imag. 2012;35:117-124.
45. Doniach D. Possible stimulation of thermogenesis in brown adipose tissue by thyroid-stimulating hormone. Lancet. 1975;2:160-161.
46. DeMambro VE, Kawai M, Clemens TL, et al. A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis. J Endocrinol. 2010;204:241-253.
47. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-2 expression in type I diabetic mice. Endocrinology. 2005;146:3622-3631.
48. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via theMAPKsignaling pathway. Exp Cell Res. 2005;309:99-109.
49. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res.. 2006;21:1648-1656.
50. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92:1517-1523.
51. Jurimae J, Jurimae T. Plasma adiponectin concentration in healthy pre-and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab. 2007;293:E42-E47.
52. Won HY, Lee JA, Park ZS, et al. Prominent bone loss mediated by RANKLand IL-17 produced byCD4Tcells in TallyHo/JngJ mice. PloS One. 2011;6:e18168.
53. Linder CC. The influence of genetic background on spontaneous and genetically engineered mouse models of complex diseases. Lab Anim. 2001;30:34-39.
54. Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res.. 2008;23:1884-1891.
55. Reyes-Garcia R, Rozas-Moreno P, Lopez-Gallardo G, et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol. 2013;50:47-52.